Lumelle A. Schneeweis

ORCID: 0000-0003-3226-0774
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Monoclonal and Polyclonal Antibodies Research
  • T-cell and B-cell Immunology
  • Immune Cell Function and Interaction
  • Lipid Membrane Structure and Behavior
  • Immunotherapy and Immune Responses
  • Bone Metabolism and Diseases
  • Lipoproteins and Cardiovascular Health
  • Bone health and treatments
  • Radiopharmaceutical Chemistry and Applications
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Force Microscopy Techniques and Applications
  • Protein purification and stability
  • Muscle metabolism and nutrition
  • Infectious Encephalopathies and Encephalitis
  • NF-κB Signaling Pathways
  • Tissue Engineering and Regenerative Medicine
  • Biochemical and Structural Characterization
  • Vitamin D Research Studies
  • Mechanical and Optical Resonators
  • Cancer Immunotherapy and Biomarkers
  • Molecular Junctions and Nanostructures
  • Bacterial Genetics and Biotechnology
  • Genomics and Chromatin Dynamics
  • Immune Response and Inflammation
  • Muscle Physiology and Disorders

Bristol-Myers Squibb (United States)
2011-2020

Bristol-Myers Squibb (Germany)
2014

Protein Express (United States)
2011

University of Pennsylvania
2005-2007

Children's Hospital of Philadelphia
2005

CSL (United States)
2003

GlaxoSmithKline (Netherlands)
1999

Pennsylvania State University
1999

Epitope mapping the specific residues of an antibody/antigen interaction can be used to support mechanistic interpretation, antibody optimization, and epitope novelty assessment. Thus, there is a strong need for methods, particularly integrative ones. Here, we report identification energetic by determining interfacial hot-spot that dominates binding affinity anti-interleukin-23 (anti-IL-23) using complementary approaches hydrogen/deuterium exchange mass spectrometry (HDX-MS), fast...

10.1021/acs.analchem.6b03058 article EN Analytical Chemistry 2017-01-10
Francesco Muntoni Barry J. Byrne Hugh J. McMillan Monique M. Ryan Brenda Wong and 95 more Juergen Dukart Amita Bansal Valérie Cosson Roxana Donisa Dreghici Maitea Guridi Michael Rabbia Hannah Staunton Giridhar Tirucherai Karl Yen Xiling Yuan Kathryn R. Wagner Irvith M. Carvajal Anjaneya Chimalakonda Jochem Gokemeijer Michael Gulianello Nicole Hellbach Alexander Kozhich Daniel Kukral Harold Malone Jere E. Meredith Mathew T. Pletcher Ginger Rakestraw Lumelle A. Schneeweis J L Swain Frank Zambito Ming Chang Lora Hamuro Feng Luo Jon E. Peterson Peter Hocknell Zhen Lou Malavi T. Madireddi Mathew T. Pletcher Clifford Bechtold Michael K. Ahlijanian Ming Chang Lora Hamuro Leslie K. Jacobsen Alexander Kozhich Feng Luo Jon E. Peterson Frank Zambito Heidemarie Kletzl Alberto Dubrovsky L. Mesa Fernando Chloca Agustin Jauregu Kristi Jones Monique M. Ryan Craig Campbell Jean K. Mah Alice Y. Ho Angela W. Chiu Vanessa D’Souza Raymy Sadowski Julie Dao Michaela Grice Tiffany Price Hugh J. McMillan Erick Sell Anna McCormick Teresa Gidaro Andrea Seferian Yann Péréon Armelle Magot Carole Vuillerot Ulrike Schara‐Schmidt Valerie Sansone Emilio Albamonte Alessandra Di Bari Jasmine Refran Francesca Salmin Giuseppe Vita Gian Luca Vita Chiara Consulo Hirofumi Komaki Akihiko Ishiyama Tsuyoshi Matsumura Toshio Saito Kana Ichihara Naoki Hayashi Kouji Terada Kenji Takehara Nobuko Hayashi Yasuhiro Takeshima A. Nascimiento Daniel Natera‐de Benito Laura Carrera‐García J. Expósito C. Ortez Julita Medina O. Moya S. Roca Alicia Rodríguez M.A. del Valle

Duchenne muscular dystrophy (DMD) is a genetic muscle disorder that manifests during early childhood and ultimately fatal. Recently approved treatments targeting the cause of DMD are limited to specific subpopulations patients, highlighting need for therapies with wider applications. Pharmacologic inhibition myostatin, an endogenous inhibitor growth produced almost exclusively in skeletal muscle, has been shown increase mass several species, including humans. Taldefgrobep alfa anti-myostatin...

10.1007/s40120-023-00570-w article EN cc-by-nc Neurology and Therapy 2024-01-08

The receptor activator of NF-kappaB (RANK) belongs to the neuregulin/tumor necrosis factor (TNF) superfamily and is activated by RANK ligand (RANK-L), a homotrimeric, TNF-like cytokine. present on surface osteoclast cell precursors, where its interaction with RANK-L induces their terminal differentiation into osteoclasts, thus increasing bone breakdown. secreted, soluble osteoprotegerin (OPG) interrupts this activation binding directly RANK-L. Therefore, maturation (and homeostasis)...

10.1074/jbc.m506366200 article EN cc-by Journal of Biological Chemistry 2005-10-09

Mounting evidence in models of both autoimmunity and chronic viral infection suggests that the outcome T cell activation is critically impacted by constellation co-stimulatory co-inhibitory receptors expressed on surface. Here, we identified a critical role for SLAM family member 2B4 (CD244) attenuating primary antigen-specific CD8+ responses presence immune modulation with selective CD28 blockade. Our results reveal specific up-regulation cells animals which signaling was blocked. However,...

10.1084/jem.20130902 article EN cc-by-nc-sa The Journal of Experimental Medicine 2014-02-03

Targeting the CD28-CD80/86 pathway with an anti-CD28 antagonist is a promising alternative to current therapies for autoimmunity. However, attempts at generating conventional mAbs lacking stimulatory activity has been challenging. In this study, we describe anti-human CD28 receptor domain Abs (dAbs) that are specific human CD28. These dAbs potent inhibitors of T cell activation, EC50 35 ± 14 ng/ml inhibition proliferation. The 53 11 in ex vivo occupancy assay corresponds vitro functional...

10.4049/jimmunol.1300470 article EN The Journal of Immunology 2013-10-01

The structure of death receptor 4 (DR4) in complex with TNF-related apoptosis-inducing ligand (TRAIL) has been determined at 3 Å resolution and compared those previously DR5–TRAIL complexes. Consistent the high sequence similarity between DR4 DR5, overall arrangement DR4–TRAIL does not differ substantially from that complex. However, subtle differences are apparent. In addition, solution interaction studies were carried out show thermodynamics binding or DR5 TRAIL.

10.1107/s2053230x15016416 article EN Acta Crystallographica Section F Structural Biology Communications 2015-09-23

Apolipoprotein E (apoE) is a key regulator of cholesterol homeostasis. Human apoE has three common isoforms, each with different risk implications for cardiovascular and neurodegenerative disease. Neither the structure lipoprotein particles nor structural consequences isoform differences are known. In this investigation, synthetic were prepared by complexing phospholipids full-length or truncated N-terminal C-terminal domains apoE. These examined calorimetry, electron microscopy, circular...

10.1021/bi050872j article EN Biochemistry 2005-08-23

It is well accepted that high levels of density lipoproteins (HDL) reduce the risk atherosclerosis in humans. Apolipoprotein A-I (apoA-I) and apoA-II are first second most common protein constituents HDL. Unlike apoA-I, detailed structural models for HDL not available. Here, we present a model reconstituted (rHDL) based on two established experimental approaches: chemical cross-linking/mass spectrometry (MS) internal reflection infrared spectroscopy. Homogeneous rHDL were reacted with...

10.1074/jbc.m610380200 article EN cc-by Journal of Biological Chemistry 2007-02-02

BMS-931699 (lulizumab pegol), a domain antibody (dAb) conjugated with 40-kDa branched polyethylene glycol, is human anti-CD28 receptor antagonist under development for the treatment of inflammatory and autoimmune diseases. In present work, minimal anticipated biologic effect level (MABEL) was determined by integrating all available preclinical data. The relevance in vitro mixed lymphocyte reaction (MLR) assay to whole blood CD28 occupancy (RO) assessment, as well relationship between RO...

10.1124/jpet.115.227249 article EN Journal of Pharmacology and Experimental Therapeutics 2015-10-06

Granulocyte colony-stimulating factor regulates neutrophil production by binding to a specific receptor, the granulocyte expressed on cells of granulocytic lineage. Recombinant forms are used clinically treat neutropenias. As part an effort develop mimics with potential for oral bioavailability, we previously identified nonpeptidyl small molecule (SB-247464) that selectively activates murine signal transduction pathways and promotes formation <i>in vivo</i>. To elucidate mechanism action...

10.1074/jbc.m209220200 article EN cc-by Journal of Biological Chemistry 2003-03-01

A kinetic analysis of dimer dissociation, TATA DNA binding, and thermal inactivation the yeast Saccharomyces cerevisiae human binding proteins (TBP) was conducted. We find that TBP dimers, like are slow to dissociate in vitro (t1/2 ∼20 min). Mild mutations crystallographic interface accelerate rate whereas severe prevent dimerization. In presence excess DNA, which measures entire active population, dissociation represents rate-limiting step binding. These findings provide a biochemical...

10.1021/bi990911p article EN Biochemistry 1999-08-01

Advances in vitro display and protein engineering yield therapeutics with affinities the picomolar range. The Gyrolab® microfluidics platform uses kinetic exclusion assay principle to measure subnanomolar solution affinities. This work describes application of Gyrolab affinity module new multi-curve analysis feature determine PD-L1 Adnectin™ positron emission tomography radioligand, which was measured as 20 pM for human PD-L1. We also report key parameters that affect signal-to-background...

10.2144/btn-2020-0080 article EN cc-by-nc-nd BioTechniques 2020-07-16

Mounting evidence in models of both autoimmunity and chronic viral infection suggests that the outcome T cell activation is critically impacted by constellation costimulatory coinhibitory receptors expressed on cells' surface. Here, we identified a critical role for SLAM family member 2B4 (CD244) attenuating primary donor-reactive CD8+ responses presence immune modulation with selective CD28 blockade. Our results reveal specific upregulation cells animals which signaling was blocked....

10.1097/00007890-201407151-01028 article EN Transplantation 2014-07-01

An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the ‘Save PDF’ action button.

10.1017/s1431927618007493 article EN Microscopy and Microanalysis 2018-08-01
Coming Soon ...